OR RE Model |
Standard Dose Model Median (95% CI) |
Unadjusted Model Median (95% CI) |
Dose Adjusted Model Median (95% CI) |
Abatacept | 1.25 (0.72 to 2.15) | 1.10 (0.73 to 1.66) | 1.24 (0.74 to 2.07) |
Adalimumab | 1.03 (0.67 to 1.54) | 1.04 (0.75 to 1.45) | 0.86 (0.51 to 1.44) |
Anakinra | 1.44 (0.80 to 2.68) | 1.19 (0.74 to 1.92) | 1.38 (0.79 to 2.41) |
Certolizumab | 1.17 (0.71 to 1.95) | 1.18 (0.77 to 1.80) | 1.17 (0.74 to 1.88) |
Etanercept | 1.38 (0.80 to 2.46) | 1.13 (0.71 to 1.81) | 1.20 (0.71 to 2.06) |
Golimumab | 1.24 (0.78 to 1.98) | 1.18 (0.81 to 1.69) | 1.15 (0.74 to 1.79) |
Infliximab | 1.55 (1.01 to 2.35)* | 1.54 (1.17 to 2.03)* | 1.45 (0.98 to 2.11) |
Rituximab | 1.54 (0.49 to 4.63) | 1.49 (0.94 to 2.40) | 1.28 (0.49 to 3.37) |
Tocilizumab | 1.31 (0.57 to 3.01) | 1.34 (0.85 to 2.10) | 1.11 (0.53 to 2.28) |
Overall | 1.28 (1.09 to 1.50)* | ||
Data points Residual deviance DIC |
(101) 113 642.73 |
(160) 178.4 1012.58 |
(163) 175.9 1016.75 |